Pharmacokinetics and Pharmacodynamics — MCQs

Pharmacokinetics and Pharmacodynamics Indian Medical PG Practice Questions and MCQs

Question 261: Which of the following drugs is NOT excreted in bile?

A. Erythromycin
B. Ampicillin
C. Rifampicin
D. Gentamicin (Correct Answer)

Explanation: **Explanation:** The correct answer is **Gentamicin**. **1. Why Gentamicin is the correct answer:** Gentamicin is an **aminoglycoside**. Aminoglycosides are highly polar, water-soluble polycationic compounds. Due to their high water solubility and lack of metabolism, they are excreted almost exclusively by the kidneys via **glomerular filtration**. They do not undergo significant biliary excretion. This is why dosage adjustment is critical in patients with renal impairment. **2. Analysis of Incorrect Options:** * **Erythromycin (Option A):** This macrolide is primarily concentrated in the liver and excreted in the **bile** in very high concentrations. Only about 2–5% is excreted in the urine. * **Ampicillin (Option B):** While many penicillins are renally excreted, ampicillin undergoes significant **enterohepatic circulation** and is excreted in high concentrations in the bile. This makes it useful for treating biliary tract infections (e.g., cholecystitis) and typhoid carriers. * **Rifampicin (Option C):** This drug is a classic example of a drug excreted via the **biliary route**. It undergoes deacetylation in the liver and is then excreted in bile; it also induces its own metabolism (auto-induction). **3. High-Yield Clinical Pearls for NEET-PG:** * **Biliary Excreted Drugs (Mnemonic: "Ceph-A-R-E"):** **Ceph**triaxone, **A**mpicillin, **R**ifampicin, **E**rythromycin. * **Gentamicin Toxicity:** Because it is cleared renally, it is associated with **Nephrotoxicity** (Acute Tubular Necrosis) and **Ototoxicity**. * **Drug of Choice for Biliary Infections:** Ampicillin or Ceftriaxone are often preferred due to their high biliary concentration. * **Rifampicin Fact:** It imparts an orange-red discoloration to urine, sweat, and tears, but its primary route of elimination remains biliary.

Question 262: Isoniazid is metabolized by which process?

A. Acetylation (Correct Answer)
B. Oxidation
C. Reduction
D. Hydrolysis

Explanation: **Explanation:** **Isoniazid (INH)**, a primary drug for tuberculosis, is metabolized in the liver primarily via **Acetylation** (Phase II reaction) [1][2]. This process is catalyzed by the enzyme **N-acetyltransferase 2 (NAT2)** [1]. 1. **Why Acetylation is Correct:** Acetylation involves the transfer of an acetyl group to the drug molecule [3], making it more water-soluble for excretion. In the case of Isoniazid, it is converted into Acetyl-isoniazid [4]. This is a classic example of a Phase II metabolic pathway that determines the drug's half-life and toxicity profile [2]. 2. **Why Other Options are Incorrect:** * **Oxidation (Phase I):** While many drugs (like Phenytoin or Warfarin) undergo oxidation via Cytochrome P450 enzymes, it is not the primary pathway for Isoniazid. * **Reduction (Phase I):** This involves the addition of hydrogen or removal of oxygen (e.g., Chloramphenicol). * **Hydrolysis (Phase I):** This involves the cleavage of a chemical bond by adding water (e.g., Esters like Procaine or Amides like Lidocaine). **High-Yield Clinical Pearls for NEET-PG:** * **Genetic Polymorphism:** The rate of acetylation is genetically determined, leading to two phenotypes [1][2]: * **Fast Acetylators:** (Common in Indians/Japanese) Require higher doses; may develop **Hepatotoxicity** due to rapid formation of the metabolite acetylhydrazine [4]. * **Slow Acetylators:** (Common in Caucasians/Egyptians) Higher risk of **Peripheral Neuropathy** due to drug accumulation [1]. * **Mnemonic (Drugs metabolized by Acetylation):** **"SHIP"** — **S**ulfonamides, **H**ydralazine, **I**soniazid, **P**rocainamide. * **Drug Interaction:** Isoniazid is a potent **enzyme inhibitor**, which can increase levels of drugs like Phenytoin.

Question 263: The term physical half-life is applicable to which of the following?

A. Repository preparations
B. Prodrugs
C. Radioactive isotopes (Correct Answer)
D. Alkylating agents

Explanation: **Explanation:** **1. Why Radioactive Isotopes is Correct:** The term **physical half-life ($t_{1/2}$)** refers to the time required for a radioactive substance to lose 50% of its radioactivity through physical decay [4]. This is a constant property of the isotope itself (e.g., Iodine-131, Technetium-99m) and is independent of biological processes. In pharmacology, this is distinct from **biological half-life**, which is the time taken for the body to eliminate half of the administered dose through metabolism and excretion [3]. **2. Why Other Options are Incorrect:** * **Repository preparations:** These are long-acting formulations (e.g., Benzathine Penicillin) designed for slow absorption. Their duration of action is governed by the **absorption rate**, not a physical decay constant. * **Prodrugs:** These are pharmacologically inactive compounds converted into active metabolites (e.g., Levodopa to Dopamine). Their kinetics are defined by **metabolic activation rates**. * **Alkylating agents:** These are cytotoxic drugs (e.g., Cyclophosphamide) that form covalent bonds with DNA. Their action is governed by **chemical reactivity and biological clearance**, not physical decay. **3. Clinical Pearls & High-Yield Facts for NEET-PG:** * **Effective Half-life ($t_e$):** In nuclear medicine, the actual rate of disappearance of a radioisotope from the body is the "Effective Half-life." It is calculated using the formula: $\frac{1}{t_e} = rac{1}{t_p} + rac{1}{t_b}$ *(where $t_p$ = physical half-life and $t_b$ = biological half-life).* * **First-order Kinetics:** Most drugs follow first-order kinetics, where half-life remains constant regardless of the dose [2]. * **Steady State:** It takes approximately **4 to 5 half-lives** to reach a steady-state concentration ($C_{ss}$) during continuous drug administration [1].

Question 264: A 57-year-old man with myocardial infarction is admitted in cardiac emergency. Which of the following drugs might cause unexpected results based on the patient's CYP2C19 genotype?

A. Prasugrel
B. Clopidogrel (Correct Answer)
C. Warfarin
D. Ticagrelor

Explanation: **Explanation:** The correct answer is **Clopidogrel**. **Mechanism and Genetic Link:** Clopidogrel is a **prodrug** that requires a two-step hepatic bioactivation to its active thiol metabolite. The enzyme **CYP2C19** plays a critical role in this conversion. Patients with specific genetic polymorphisms (e.g., *CYP2C19\*2* or *\*3* alleles) are "poor metabolizers." In these individuals, clopidogrel is not efficiently converted to its active form, leading to reduced platelet inhibition and an increased risk of major adverse cardiovascular events (MACE), such as stent thrombosis or recurrent MI. **Analysis of Incorrect Options:** * **Prasugrel:** While also a prodrug, its activation is more efficient and involves multiple enzymes (CYP3A4, CYP2B6). It is significantly less dependent on CYP2C19 than clopidogrel. * **Warfarin:** Its metabolism is primarily influenced by **CYP2C9** (not 2C19) and its pharmacodynamics are affected by the **VKORC1** gene. * **Ticagrelor:** This is a **direct-acting** P2Y12 inhibitor. It is not a prodrug and does not require metabolic activation; therefore, its efficacy is not affected by CYP2C19 polymorphisms. **High-Yield NEET-PG Pearls:** * **Black Box Warning:** The FDA has a boxed warning for Clopidogrel regarding its reduced effectiveness in CYP2C19 poor metabolizers. * **Drug Interaction:** **Omeprazole** (a proton pump inhibitor) inhibits CYP2C19 and can reduce the clinical efficacy of clopidogrel. If a PPI is needed, Pantoprazole is preferred as it has less inhibitory effect on CYP2C19. * **Alternative:** In known poor metabolizers, Prasugrel or Ticagrelor are the preferred antiplatelet agents.

Question 265: What is the most important factor affecting drug absorption in the gastrointestinal tract?

A. Lipid solubility (Correct Answer)
B. Protein binding
C. P-glycoprotein
D. Physical state of the drug

Explanation: **Explanation:** **1. Why Lipid Solubility is Correct:** The primary mechanism for drug absorption in the gastrointestinal tract is **passive diffusion** across the cell membrane. Since the cell membrane is a phospholipid bilayer, a drug must be lipid-soluble to dissolve in the membrane and pass through it. According to **Fick’s Law of Diffusion**, the rate of movement is directly proportional to the lipid-water partition coefficient. Therefore, high lipid solubility is the most critical factor determining the extent and rate of absorption for the majority of drugs. **2. Why Other Options are Incorrect:** * **Protein Binding:** This affects the **distribution** and elimination of a drug, not its initial absorption. Only the free (unbound) fraction of a drug is pharmacologically active, but binding occurs primarily in the plasma *after* absorption. * **P-glycoprotein:** This is an efflux transporter that can *decrease* the net absorption of certain drugs (like digoxin) by pumping them back into the intestinal lumen. While important, it is a specific regulatory mechanism rather than the primary determinant of general drug absorption. * **Physical state of the drug:** While liquids are generally absorbed faster than solids (tablets/capsules), this relates more to the **rate of dissolution** rather than the inherent ability of the drug molecule to cross the biological membrane. **Clinical Pearls for NEET-PG:** * **pH and Ionization:** Only the **un-ionized** form of a drug is lipid-soluble and can cross membranes. * **Surface Area:** The **small intestine** is the major site of absorption for most drugs (even weak acids) due to its massive surface area (villi/microvilli), regardless of the drug's ionization state. * **Bioavailability:** This refers to the fraction of an administered dose that reaches the systemic circulation in an unchanged form. Lipid solubility is a key determinant of oral bioavailability.

Question 266: Slow acetylators of isoniazid are more prone to develop which of the following?

A. Failure of therapy
B. Peripheral neuropathy (Correct Answer)
C. Hepatotoxicity
D. Allergic reactions

Explanation: **Explanation:** The metabolism of **Isoniazid (INH)** occurs primarily in the liver via **N-acetylation** by the enzyme **N-acetyltransferase 2 (NAT2)**. This process is genetically determined, leading to two distinct phenotypes: fast acetylators and slow acetylators. **Why Peripheral Neuropathy is Correct:** In **slow acetylators**, the rate of metabolism is reduced, leading to higher plasma concentrations of Isoniazid. Isoniazid promotes the excretion of **Pyridoxine (Vitamin B6)** and inhibits the enzyme pyridoxine kinase. Higher levels of the drug result in a more profound deficiency of Vitamin B6, which is essential for myelin sheath integrity. This leads to **peripheral neuropathy**. To prevent this, 10–50 mg/day of Pyridoxine is co-administered with INH. **Analysis of Incorrect Options:** * **A. Failure of therapy:** This is more common in **fast acetylators** because the drug is metabolized and cleared too quickly, potentially falling below the therapeutic window. * **C. Hepatotoxicity:** While Isoniazid causes liver injury, it is traditionally associated more with **fast acetylators**. This is because fast acetylation produces more **acetyl-hydrazine**, a toxic metabolite that causes oxidative stress in hepatocytes. (Note: Recent studies show a complex relationship, but for NEET-PG, fast acetylation = hepatotoxicity; slow acetylation = neuropathy). * **D. Allergic reactions:** These are idiosyncratic and not directly linked to the acetylation status or the pharmacokinetic profile of the drug. **High-Yield Clinical Pearls for NEET-PG:** * **Genetic Polymorphism:** NAT2 deficiency is an example of pharmacogenetic variation. * **Other drugs metabolized by Acetylation:** Remember the mnemonic **SHIP** (Sulfonamides, Hydralazine, Isoniazid, Procainamide). * **Drug-Induced Lupus:** Slow acetylators are also at a higher risk of developing Drug-Induced Lupus Erythematosus (DILE) when taking Hydralazine or Procainamide.

Question 267: A drug is administered in a dose of 200 mg and its plasma concentration is 40 microgram/ml. What is the volume of distribution?

A. 5 litres (Correct Answer)
B. 0.5 litres
C. 2.5 litres
D. 3 litres

Explanation: ### Explanation **1. Understanding the Correct Answer (A: 5 Litres)** The **Volume of Distribution ($V_d$)** is a theoretical volume that relates the total amount of drug in the body to the concentration of the drug in the plasma. It is calculated using the formula: $$V_d = \frac{\text{Total Amount of Drug (Dose)}}{\text{Plasma Concentration (C)}}$$ **Calculation:** * **Dose:** 200 mg * **Plasma Concentration:** 40 µg/ml. To maintain unit consistency, convert µg/ml to mg/L (Note: 1 µg/ml = 1 mg/L). Therefore, 40 µg/ml = 40 mg/L. * $V_d = \frac{200\text{ mg}}{40\text{ mg/L}} = \mathbf{5\text{ Litres}}$ A $V_d$ of 5L suggests the drug is primarily confined to the vascular compartment (plasma volume). **2. Analysis of Incorrect Options** * **B (0.5 L):** This value is too low for a human adult; even plasma volume is approximately 3L. This result occurs if one incorrectly divides 20 by 40. * **C (2.5 L) & D (3 L):** These values do not satisfy the mathematical ratio of the given dose and concentration. A $V_d$ of 3L would represent the average plasma volume, but it does not fit the specific parameters of this question. **3. Clinical Pearls & High-Yield Facts for NEET-PG** * **Low $V_d$ (< 5L):** Drug is confined to plasma (e.g., **Warfarin, Heparin**). These drugs are often highly protein-bound. * **Medium $V_d$ (10–20L):** Drug distributes into extracellular fluid (e.g., **Aminoglycosides**). * **High $V_d$ (> 42L):** Drug sequesters in tissues/fat (e.g., **Digoxin, Chloroquine**). These drugs cannot be removed by hemodialysis during toxicity. * **Loading Dose:** $V_d$ is the primary determinant used to calculate the Loading Dose ($LD = V_d \times \text{Target } C_p$).

Question 268: Which of the following drugs is metabolized by acetylation?

A. Phenytoin
B. Isoniazid (Correct Answer)
C. Salbutamol
D. Haloperidol

Explanation: **Explanation:** **Isoniazid (Option B)** is the correct answer because it is primarily metabolized via **Phase II Acetylation** by the enzyme **N-acetyltransferase (NAT2)**. In pharmacology, drugs metabolized by acetylation are high-yield for exams because of **genetic polymorphism**. Individuals are classified as "Fast Acetylators" (who may require higher doses) or "Slow Acetylators" (who are at a higher risk of toxicity, such as peripheral neuropathy). **Analysis of Incorrect Options:** * **Phenytoin (Option A):** Metabolized primarily by **Phase I Oxidation** (CYP2C9 and CYP2C19). It follows zero-order kinetics at therapeutic/higher concentrations. * **Salbutamol (Option C):** Primarily undergoes **Sulfate Conjugation** (Phase II) in the GI tract and liver. * **Haloperidol (Option D):** Metabolized mainly through **Oxidative N-dealkylation** and **Glucuronidation**. **High-Yield Clinical Pearls for NEET-PG:** To remember drugs metabolized by acetylation, use the mnemonic **"SHIP"**: * **S** – Sulfonamides (e.g., Sulfadiazine) * **H** – Hydralazine * **I** – Isoniazid * **P** – Procainamide **Key Fact:** Slow acetylators are prone to **Drug-Induced Lupus Erythematosus (DILE)** when taking Hydralazine, Procainamide, or Isoniazid. For Isoniazid specifically, slow acetylators have a higher risk of **peripheral neuropathy**, while fast acetylators may have a higher risk of **hepatotoxicity** due to the rapid formation of the metabolite acetylhydrazine.

Question 269: Which of the following metabolic reactions is not catalyzed by microsomal enzymes?

A. Glucuronidation
B. Acetylation (Correct Answer)
C. Oxidation
D. Reduction

Explanation: **Explanation:** Metabolic reactions in the liver are categorized based on the location of the enzymes involved: **Microsomal** (located in the smooth endoplasmic reticulum) and **Non-microsomal** (located in the cytoplasm or mitochondria). **Why Acetylation is the correct answer:** Acetylation is a Phase II conjugation reaction catalyzed by the enzyme **N-acetyltransferase (NAT)**. This enzyme is located in the **cytoplasm** (non-microsomal) of hepatocytes and other tissues. Therefore, it does not occur within the microsomal fraction of the cell. **Analysis of Incorrect Options:** * **Glucuronidation (Option A):** This is the **only Phase II reaction** catalyzed by microsomal enzymes (specifically, UDP-glucuronosyltransferases or UGTs). It is the most common conjugation pathway. * **Oxidation (Option C):** Most Phase I oxidative reactions are catalyzed by the **Cytochrome P450 (CYP450)** system, which is the hallmark of microsomal enzymes. * **Reduction (Option D):** Many reduction reactions (e.g., chloramphenicol metabolism) are carried out by microsomal enzymes, though some non-microsomal pathways also exist. **High-Yield Clinical Pearls for NEET-PG:** * **Microsomal Enzymes:** These are inducible (by drugs like Phenobarbitone/Rifampicin) and primarily include CYP450 enzymes and UGT. * **Non-microsomal Enzymes:** These are generally **non-inducible**. Examples include Acetylation, Sulfation, Methylation, and Alcohol Dehydrogenase. * **Acetylation Polymorphism:** Drugs like **Isoniazid (INH), Hydralazine, Procainamide, and Sulfonamides** (Mnemonic: **SHIP**) undergo acetylation. Patients are classified as "Fast" or "Slow" acetylators, which determines their risk for toxicity (e.g., peripheral neuropathy with INH in slow acetylators).

Question 270: Which of the following is FALSE regarding sustained-release tablets?

A. They release the drug at a constant rate.
B. They have less chances of toxicity. (Correct Answer)
C. They contain a large amount of the drug.
D. The margin of safety is an important consideration for their formulation.

Explanation: **Explanation:** Sustained-release (SR) or extended-release formulations are designed to maintain therapeutic drug concentrations for a prolonged period. **Why Option B is FALSE (The Correct Answer):** Contrary to common belief, SR tablets actually carry a **higher risk of toxicity** if the delivery mechanism fails. This phenomenon is known as **"Dose Dumping,"** where the entire large dose intended for 12–24 hours is released prematurely into the systemic circulation. This can lead to fatal toxicity, especially in drugs with a narrow therapeutic index. Therefore, saying they have "less chances of toxicity" is clinically incorrect. **Analysis of Other Options:** * **Option A:** The goal of SR formulations is to provide **Zero-order kinetics**, releasing the drug at a constant rate independent of the amount remaining in the tablet to maintain steady-state plasma levels. * **Option C:** To provide therapeutic effects over an extended duration (e.g., 24 hours), these tablets must contain a **significantly higher total dose** of the drug compared to immediate-release versions. * **Option D:** Because of the risk of dose dumping, the **margin of safety (Therapeutic Index)** is a critical consideration. Drugs with a very narrow therapeutic window (e.g., Digoxin) are generally not preferred for SR formulations unless the delivery technology is exceptionally robust. **High-Yield NEET-PG Pearls:** * **Zero-order kinetics:** Rate of elimination/release is constant (independent of concentration). * **Dose Dumping:** Triggered by crushing the tablet or, in some cases, consuming alcohol with the medication. * **Contraindication:** SR tablets should **never be crushed or chewed**, as this destroys the release matrix. * **Ideal Candidates:** Drugs with short half-lives ($t_{1/2} < 4$ hours) are the best candidates for SR formulations to improve patient compliance.

Practice by Chapter

Absorption and Bioavailability

Practice Questions

Drug Distribution and Protein Binding

Practice Questions

Biotransformation and Metabolism Pathways

Practice Questions

Renal and Non-renal Excretion

Practice Questions

Compartment Models

Practice Questions

Dose-Response Relationships

Practice Questions

Drug Efficacy and Potency

Practice Questions

Drug Tolerance and Tachyphylaxis

Practice Questions

Population Pharmacokinetics

Practice Questions

Pharmacokinetic Variability

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free